Celldex (CLDX) stock was on the move Monday after the biopharmaceutical company received bullish coverage from five-star Barclays analyst Etzer Darout. The analyst hit CLDX stock with a double upgrade, now rating the stock as Overweight instead of Underweight. To go along with that, he boosted his price target to $45 from $25, representing a potential 30.25% upside for the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to Darout, the firm “can’t ignore” Celldex following the company’s latest clinical trial results. The company provided positive results from its Phase 3 clinical trial of its chronic spontaneous urticaria treatment, barzolvolimab. The trial reached recruitment numbers ahead of schedule and posted strong results in Q4 2025. Darout argued this showed strong demand for barzolvolimab.
All of the recent clinical updates from Celldex have been positive, which have won over Darout. Investors have taken note of this, as he was one of the few Wall Street analysts who was still bearish on the stock prior to today’s update.
Celldex Stock Movement Today
While Celldex stock rallied in premarket trading on Monday, the shares gave up those gains after the opening bell. This has the stock down slightly this morning. Even so, the shares have increased 27.21% year-to-date and 82.42% over the past 12 months.
CLDX stock trading activity today saw some 95,000 shares change hands. This is below the stock’s three-month average daily trading volume of about 1.17 million shares.
Is Celldex Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Celldex is Strong Buy, based on 10 Buy and one Hold rating over the past three months. With that comes an average CLDX stock price target of $56.60, representing a potential 63.92% upside for the shares.
